Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Press/Media

Period	14 Feb 2023

Media coverage

Title	Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Media name/outlet	PipelineReview
Country/Territory	Spain
Date	14/02/23
URL	ct.moreover.com/?a=50004943493&p=1gw&v=1&x=R3X6cM6qT04FsIbFkDAWIg
Persons	Mauricio Burotto